Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 3Other 2

Conditions

Drug-Related Side Effects and Adverse Reactions 19Head and Neck Neoplasms 15Lung Neoplasms 12Radiation Injuries 11Ovarian Neoplasms 10Leukemia 9Squamous Cell Carcinoma of Head and Neck 8Carcinoma, Ovarian Epithelial 8Carcinoma, Non-Small-Cell Lung 8Leukemia, Myeloid, Acute 7Sarcoma 6Lymphoma, Non-Hodgkin 6Lymphoma 6Hodgkin Disease 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Myelodysplastic Syndromes 5Lymphoma, Mantle-Cell 5Lymphoma, Large-Cell, Immunoblastic 5Lymphoma, Large B-Cell, Diffuse 5Lymphoma, Follicular 5Lymphoma, B-Cell, Marginal Zone 5Leukemia, Lymphocytic, Chronic, B-Cell 5Burkitt Lymphoma 5Breast Neoplasms 5Neurotoxicity Syndromes 4Multiple Myeloma 4Xerostomia 3Waldenstrom Macroglobulinemia 3Uterine Cervical Neoplasms 3Testicular Neoplasms 3

Interventions

Radiotherapy 6Radiation 4Low-Level Light Therapy 4Cisplatin 3Amifostine 3Acupuncture Therapy 3Surveys and Questionnaires 2Surgical Procedures, Operative 2Standard of Care 2Saliva, Artificial 2Pilocarpine 2Oral Hygiene 2Chewing Gum 2pegfilgrastim 1ginger extract 1citric acid, deuterium oxide solution 1Xylitol 1Transcutaneous Electric Nerve Stimulation 1Selenomethionine 1Respiration 1Paclitaxel 1Mouthwashes 1Lansoprazole 1Hypnosis 1Health Education, Dental 1Granulocyte Colony-Stimulating Factor 1Genetic Engineering 1Fluorouracil 1Filgrastim 1Fibroblast Growth Factor 7 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Xerostomia × Amifostine × Clear all
NCT00503776 2017-06-20

Chemo/XRT +/- Amifostine to Assess Outcomes Related to Xerostomia, Mucositis, & Dysphagia

Vanderbilt-Ingram Cancer Center

Phase 2 Terminated
41 enrolled 12 charts
Head & NeckOther

Squamous Cell Carcinoma of Head and Neck, Deglutition Disorders, Head and Neck Neoplasms, Radiation Injuries, Salivary Gland Neoplasms, Xerostomia, Mucositis

NCT00095927 2017-01-04

Randomized Amifostine For SCCHN

Dana-Farber Cancer Institute

Phase 2 Completed
58 enrolled
Head & NeckOther

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Radiation Injuries, Xerostomia, Mucositis

NCT00158691 2005-09-12

Intravenous Versus Subcutaneous Amifostine in Prevention of Xerostomia After RT for Head and Neck Carcinomas

Groupe Oncologie Radiotherapie Tete et Cou

Phase 3 Completed
296 enrolled
Head & Neck

Head and Neck Neoplasms, Xerostomia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡